A plausible candidate SNP for future studies is a homozygous variant (309 G/G) of the p53‐modulator, MDM2, which has been suggested as a potential risk factor for development of visceral KS, PEL or MCD after the heterozygous form was found to be associated with cutaneous classic KS in Caucasians and the homozygous form identified in a number of PEL cell lines.59, 92. This evidence concerns the gene TP53 and Kaposi's sarcoma.